Edwards Invests In Mitral, Tricuspid Solutions As TAVR Growth Exceeds Expectations

Sales of Sapien transcatheter aortic valves grew about 27% year over year in the third quarter of 2019 while revenues from Edwards’ transcatheter mitral and tricuspid therapies grew to almost $10m, led by sales of the Pascal transcatheter mitral repair system in Europe.

MT1910_Third Quarter_292136531_1200.jpg
• Source: shutterstock.com

Edwards Lifesciences Corp. expects revenues from its transcatheter mitral and tricuspid valve therapies (TMTT) to double in 2020.

Edwards' is projecting TMTT revenue will be under $40m for all of 2019, but climb to $80m in 2020 after the company brings the Pascal mitral valve repair device to...

More from Business

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.